Cited by 436Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning

Schenk, Dale·2002·Nature Reviews Neuroscience

Integrity signals

Registry

Crossref · 10.1038/nrn938

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Schenk, D.
Affiliations
Elan Pharmaceuticals, Inc. (Ireland) (IE)
Corresponding author
Schenk, Dale
Venue
Nature Reviews Neuroscience
Published
2002-10
Volume
3
Issue
10
Pages
824-828
ISSN
  • 1471-003X (ISSN-L)
  • 1471-0048
OpenAlex
W2050181337
Cited by
436
References
22
Citations by year
2026: 2 · 2025: 4 · 2024: 7 · 2023: 9 · 2022: 4 · 2021: 10 · 2020: 7 · 2019: 5 · 2018: 5 · 2017: 12 · 2016: 10 · 2015: 12 · 2014: 20 · 2013: 26 · 2012: 19
FWCI
5.19
Type
journal article
Language
en
Open access
closed
Locations
  • Nature reviews. Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid-beta immunotherapy, Alzheimer's disease, amyloid hypothesis, active immunization, passive immunization, anti-amyloid antibodies, clinical trials, disease progression, neurodegeneration, cognitive function
MeSH terms
Alzheimer Disease, Animals, Antibodies, Antibodies, Monoclonal, Disease Models, Animal, Humans, Immunization, Passive, Meningoencephalitis, Mice, Transgenic, Peptide Fragments, Vaccines, Amyloid beta-Peptides, Immunotherapy, Active, Treatment Outcome, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review